Hui Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui Luo has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Qibin Jiao
School of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121, China
3 shared publications - Wenyan Gong
Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China
3 shared publications - Xingwei Zhang
School of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China
3 shared publications Zhen Chen
School of Clinical Medicine, Hangzhou Normal University, Hangzhou 311121, China
3 shared publicationsWen-Yan Gong
School of Clinical Medicine, Hangzhou Normal University, Hangzhou 311121, China
2 shared publicationsYing-Ying Liu
School of Clinical Medicine, Hangzhou Normal University, Hangzhou 311121, China
2 shared publications
Latest Publications
- 15 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1030, 179145
DGAT2: A key therapeutic target in lipid synthesis regulation and metabolic diseases
- 15 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1030, 179145
DGAT2: A key therapeutic target in lipid synthesis regulation and metabolic diseases
- Open Access
- 16 February 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2627053
Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5 H -pyrrolo[3,4- d ]pyrimidine-based PARP1/ATR dual inhibitors
PARP1 inhibitors are FDA-approved for BRCA1/2-mutated breast cancer but show limited efficacy in wild-type cancers and face resistance issues. To overcome these, we designed novel 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based compounds integrating PARP1 inhibitor pharmacophores with the ATR inhibitor AZD6738 scaffold. Substituent modifications influenced PARP1 and ATR selectivity, yielding dual inhibitors or selective PARP1 inhibitors. Compound 38a, the lead candidate, exhibited potent dual inhibition (IC50 < 20 nM) and strong antitumor effects in MDA-MB-231 (IC50 < 0.048 μM) and MDA-MB-468 (IC50: 0.01 μM) cell lines in vitro. Mechanistically, 38a arrested cell cycle progression, induced apoptosis, inhibited colony formation and migration, and suppressed DNA damage repair pathways, outperforming combined Niraparib and AZD6738. These findings underscore the therapeutic potential of PARP1/ATR dual inhibitors for breast cancer and support further investigation.
- 16 February 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2627053
Open AccessDesign, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5 H -pyrrolo[3,4- d ]pyrimidine-based PARP1/ATR dual inhibitors
PARP1 inhibitors are FDA-approved for BRCA1/2-mutated breast cancer but show limited efficacy in wild-type cancers and face resistance issues. To overcome these, we designed novel 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based compounds integrating PARP1 inhibitor pharmacophores with the ATR inhibitor AZD6738 scaffold. Substituent modifications influenced PARP1 and ATR selectivity, yielding dual inhibitors or selective PARP1 inhibitors. Compound 38a, the lead candidate, exhibited potent dual inhibition (IC50 < 20 nM) and strong antitumor effects in MDA-MB-231 (IC50 < 0.048 μM) and MDA-MB-468 (IC50: 0.01 μM) cell lines in vitro. Mechanistically, 38a arrested cell cycle progression, induced apoptosis, inhibited colony formation and migration, and suppressed DNA damage repair pathways, outperforming combined Niraparib and AZD6738. These findings underscore the therapeutic potential of PARP1/ATR dual inhibitors for breast cancer and support further investigation.
- 2 December 2025
- Published by Wiley in Cell Biochemistry and Function
- Vol. 43 (12) , e70149
Exploring the Impact of NRF2 Signaling on Atherosclerosis: Insights Into Hydrogen Sulfide, NLRP3 Inflammasome, microRNAs, and HO‐1
Atherosclerosis (AS) is a chronic cardiovascular disorder characterized by lipid accumulation and the formation of atherosclerotic plaques on the arterial walls, leading to arterial stenosis and serving as a principal pathological feature. This condition significantly contributes to elevated mortality and disability rates globally. The NRF2 pathway plays a pivotal role in the pathogenesis of AS. It governs a variety of physiological and pathophysiological processes including lipid homeostasis, foam cell formation, macrophage polarization, redox balance and inflammation, which are integral to the progression of the disease. This review highlights the influence of NRF2 on AS by discussing its upstream regulator hydrogen sulfide (H₂S) and key downstream effectors such as the NLRP3 inflammasome, microRNAs, and heme oxygenase‐1.
- 2 December 2025
- Published by Wiley in Cell Biochemistry and Function
- Vol. 43 (12) , e70149
Exploring the Impact of NRF2 Signaling on Atherosclerosis: Insights Into Hydrogen Sulfide, NLRP3 Inflammasome, microRNAs, and HO‐1
Atherosclerosis (AS) is a chronic cardiovascular disorder characterized by lipid accumulation and the formation of atherosclerotic plaques on the arterial walls, leading to arterial stenosis and serving as a principal pathological feature. This condition significantly contributes to elevated mortality and disability rates globally. The NRF2 pathway plays a pivotal role in the pathogenesis of AS. It governs a variety of physiological and pathophysiological processes including lipid homeostasis, foam cell formation, macrophage polarization, redox balance and inflammation, which are integral to the progression of the disease. This review highlights the influence of NRF2 on AS by discussing its upstream regulator hydrogen sulfide (H₂S) and key downstream effectors such as the NLRP3 inflammasome, microRNAs, and heme oxygenase‐1.
- 15 September 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156055
Cardioprotective effects of polydatin against myocardial injury in HFD/stz and high glucose-induced diabetes via a Caveolin 1-dependent mechanism
- 15 September 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156055
Cardioprotective effects of polydatin against myocardial injury in HFD/stz and high glucose-induced diabetes via a Caveolin 1-dependent mechanism
- 5 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23221
UFMylation of HRD1 regulates endoplasmic reticulum homeostasis
Ubiquitin fold modifier 1 is a small ubiquitin‐like protein modifier that is essential for embryonic development of metazoans. Although UFMylation has been connected to endoplasmic reticulum homeostasis, the underlying mechanisms and the relevant cellular targets are largely unknown. Here, we show that HRD1, a ubiquitin ligase of ER‐associated protein degradation (ERAD), is a novel substrate of UFM1 conjugation. HRD1 interacts with UFMylation components UFL1 and DDRGK1 and is UFMylated at Lys610 residue. In UFL1‐depleted cells, the stability of HRD1 is increased and its ubiquitination modification is reduced. In the event of ER stress, the UFMylation and ubiquitination modification of HRD1 is gradually inhibited over time. Alteration of HRD1 Lys610 residue to arginine impairs its ability to degrade unfolded or misfolded proteins to disturb protein processing in ER. These results suggest that UFMylation of HRD1 facilitates ERAD function to maintain ER homeostasis.
- 5 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23221
UFMylation of HRD1 regulates endoplasmic reticulum homeostasis
Ubiquitin fold modifier 1 is a small ubiquitin‐like protein modifier that is essential for embryonic development of metazoans. Although UFMylation has been connected to endoplasmic reticulum homeostasis, the underlying mechanisms and the relevant cellular targets are largely unknown. Here, we show that HRD1, a ubiquitin ligase of ER‐associated protein degradation (ERAD), is a novel substrate of UFM1 conjugation. HRD1 interacts with UFMylation components UFL1 and DDRGK1 and is UFMylated at Lys610 residue. In UFL1‐depleted cells, the stability of HRD1 is increased and its ubiquitination modification is reduced. In the event of ER stress, the UFMylation and ubiquitination modification of HRD1 is gradually inhibited over time. Alteration of HRD1 Lys610 residue to arginine impairs its ability to degrade unfolded or misfolded proteins to disturb protein processing in ER. These results suggest that UFMylation of HRD1 facilitates ERAD function to maintain ER homeostasis.
- Open Access
- 29 June 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1123769
Unraveling the roles of endoplasmic reticulum-associated degradation in metabolic disorders
Misfolded proteins retained in the endoplasmic reticulum cause many human diseases. ER-associated degradation (ERAD) is one of the protein quality and quantity control system located at ER, which is responsible for translocating the misfolded proteins or properly folded but excess proteins out of the ER for proteasomal degradation. Recent studies have revealed that mice with ERAD deficiency in specific cell types exhibit impaired metabolism homeostasis and metabolic diseases. Here, we highlight the ERAD physiological functions in metabolic disorders in a substrate-dependent and cell type-specific manner.
- 29 June 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1123769
Open AccessUnraveling the roles of endoplasmic reticulum-associated degradation in metabolic disorders
Misfolded proteins retained in the endoplasmic reticulum cause many human diseases. ER-associated degradation (ERAD) is one of the protein quality and quantity control system located at ER, which is responsible for translocating the misfolded proteins or properly folded but excess proteins out of the ER for proteasomal degradation. Recent studies have revealed that mice with ERAD deficiency in specific cell types exhibit impaired metabolism homeostasis and metabolic diseases. Here, we highlight the ERAD physiological functions in metabolic disorders in a substrate-dependent and cell type-specific manner.
- Open Access
- 6 May 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (5) , 1223
Association between Intestinal Microecological Changes and Atherothrombosis
Atherosclerosis (AS) is a chronic inflammatory disease of large- and medium-sized arteries that causes ischemic heart disease, strokes, and peripheral vascular disease, collectively called cardiovascular disease (CVD), and is the leading cause of CVD resulting in a high rate of mortality in the population. AS is pathological by plaque development, which is caused by lipid infiltration in the vessel wall, endothelial dysfunction, and chronic low-grade inflammation. Recently, more and more scholars have paid attention to the importance of intestinal microecological disorders in the occurrence and development of AS. Intestinal G-bacterial cell wall lipopolysaccharide (LPS) and bacterial metabolites, such as oxidized trimethylamine (TMAO) and short-chain fatty acids (SCFAs), are involved in the development of AS by affecting the inflammatory response, lipid metabolism, and blood pressure regulation of the body. Additionally, intestinal microecology promotes the progression of AS by interfering with the normal bile acid metabolism of the body. In this review, we summarize the research on the correlation between maintaining a dynamic balance of intestinal microecology and AS, which may be potentially helpful for the treatment of AS.
- 6 May 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (5) , 1223
Open AccessAssociation between Intestinal Microecological Changes and Atherothrombosis
Atherosclerosis (AS) is a chronic inflammatory disease of large- and medium-sized arteries that causes ischemic heart disease, strokes, and peripheral vascular disease, collectively called cardiovascular disease (CVD), and is the leading cause of CVD resulting in a high rate of mortality in the population. AS is pathological by plaque development, which is caused by lipid infiltration in the vessel wall, endothelial dysfunction, and chronic low-grade inflammation. Recently, more and more scholars have paid attention to the importance of intestinal microecological disorders in the occurrence and development of AS. Intestinal G-bacterial cell wall lipopolysaccharide (LPS) and bacterial metabolites, such as oxidized trimethylamine (TMAO) and short-chain fatty acids (SCFAs), are involved in the development of AS by affecting the inflammatory response, lipid metabolism, and blood pressure regulation of the body. Additionally, intestinal microecology promotes the progression of AS by interfering with the normal bile acid metabolism of the body. In this review, we summarize the research on the correlation between maintaining a dynamic balance of intestinal microecology and AS, which may be potentially helpful for the treatment of AS.